- Home
- TSLX vs RCKT Comparison
TSLX vs RCKT Comparison
Compare TSLX & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSLX
- RCKT
- Stock Information
- Founded
- TSLX 2010
- RCKT 1999
- Country
- TSLX United States
- RCKT United States
- Employees
- TSLX N/A
- RCKT N/A
- Industry
- TSLX Investment Managers
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- TSLX Finance
- RCKT Health Care
- Exchange
- TSLX Nasdaq
- RCKT Nasdaq
- Market Cap
- TSLX 2.1B
- RCKT 326.4M
- IPO Year
- TSLX 2014
- RCKT N/A
- Fundamental
- Price
- TSLX $24.10
- RCKT $2.95
- Analyst Decision
- TSLX Strong Buy
- RCKT Buy
- Analyst Count
- TSLX 8
- RCKT 13
- Target Price
- TSLX $22.69
- RCKT $18.50
- AVG Volume (30 Days)
- TSLX 598.4K
- RCKT 4.3M
- Earning Date
- TSLX 07-30-2025
- RCKT 08-04-2025
- Dividend Yield
- TSLX 8.54%
- RCKT N/A
- EPS Growth
- TSLX N/A
- RCKT N/A
- EPS
- TSLX 1.89
- RCKT N/A
- Revenue
- TSLX $481,092,000.00
- RCKT N/A
- Revenue This Year
- TSLX N/A
- RCKT N/A
- Revenue Next Year
- TSLX N/A
- RCKT N/A
- P/E Ratio
- TSLX $12.90
- RCKT N/A
- Revenue Growth
- TSLX 4.73
- RCKT N/A
- 52 Week Low
- TSLX $18.58
- RCKT $2.19
- 52 Week High
- TSLX $24.42
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- TSLX 71.44
- RCKT 41.69
- Support Level
- TSLX $23.67
- RCKT $2.40
- Resistance Level
- TSLX $23.98
- RCKT $2.70
- Average True Range (ATR)
- TSLX 0.39
- RCKT 0.21
- MACD
- TSLX 0.06
- RCKT 0.15
- Stochastic Oscillator
- TSLX 97.46
- RCKT 73.53
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.